J
J. Otto
Publications - 17
Citations - 578
J. Otto is an academic researcher. The author has contributed to research in topics: ROS1 & Lung cancer. The author has an hindex of 7, co-authored 15 publications receiving 377 citations.
Papers
More filters
Journal ArticleDOI
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
Michael Duruisseaux,Benjamin Besse,Jacques Cadranel,Maurice Pérol,Bertrand Mennecier,Laurence Bigay-Game,Renaud Descourt,Eric Dansin,Clarisse Audigier-Valette,L. Moreau,José Hureaux,Remi Veillon,J. Otto,Anne Madroszyk-Flandin,Alexis B. Cortot,François Guichard,Pascaline Boudou-Rouquette,Alexandra Langlais,P. Missy,Franck Morin,Denis Moro-Sibilot +20 more
TL;DR: Next-generation ALKi treatment correlated with better survival outcomes in multivariable analysis, indicating that unselected ALK-positive NSCLC patients achieve good survival outcomes with crizotinib therapy.
Journal ArticleDOI
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.
Jean-Louis Pujol,Laurent Greillier,Clarisse Audigier-Valette,Denis Moro-Sibilot,Lionel Uwer,José Hureaux,Florian Guisier,Delphine Carmier,Jeannick Madelaine,J. Otto,Valérie Gounant,Patrick Merle,Pierre Mourlanette,Olivier Molinier,Aldo Renault,Audrey Rabeau,Martine Antoine,Marc G. Denis,Sébastien Bommart,Alexandra Langlais,Franck Morin,Pierre-Jean Souquet +21 more
TL;DR: Atezolizumab monotherapy in relapsed SCLC failed to show significant efficacy and no unexpected safety concerns were observed.
Journal ArticleDOI
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Denis Moro-Sibilot,Nathalie Cozic,Maurice Pérol,Julien Mazieres,J. Otto,P.J. Souquet,Ratislav Bahleda,Marie Wislez,Gérard Zalcman,Gérard Zalcman,S.D. Guibert,Fabrice Barlesi,Bertrand Mennecier,Isabelle Monnet,Renaud Sabatier,S. Bota,C. Dubos,V. Verriele,Véronique Haddad,Gilbert Ferretti,Alexis B. Cortot,F. De Fraipont,Marta Jimenez,N. Hoog-Labouret,Gilles Vassal +24 more
TL;DR: There are signs of late response not sufficient to justify the development of crizotinib in patients with ROS1-translocated tumours, but the continued targeting of c-MET with innovative therapies appears justified.
Journal ArticleDOI
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.
Julien Mazieres,Claire Cropet,L. Montané,Fabrice Barlesi,P.J. Souquet,Xavier Quantin,Catherine Dubos-Arvis,J. Otto,L. Favier,V. Avrillon,Jacques Cadranel,Denis Moro-Sibilot,Isabelle Monnet,Virginie Westeel,J. Le Treut,Etienne Brain,Jean Trédaniel,M. Jaffro,Samia Collot,Gilbert Ferretti,C. Tiffon,C. Mahier-Ait Oukhatar,J.-Y. Blay +22 more
TL;DR: Routine biomarker screening of NSCLC should include BRAFV600 mutations and vemurafenib monotherapy is effective for treating patients with BRAfV600-mutated NSCLc but not those with BRAFnonV 600 mutations.
Journal ArticleDOI
Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial.
Denis Moro-Sibilot,Laura Faivre,Gérard Zalcman,Maurice Pérol,Fabrice Barlesi,J. Otto,Isabelle Monnet,Alexis B. Cortot,Marie Wislez,Hervé Lena,Julien Mazieres,Xavier Durando,Sylvie Lantuejoul,Isabelle Rouquette,Anne McLeer Florin,Gilbert Ferretti,Natalie Hoog Labouret,Frederique Nowak,Marta Jimenez,Gilles Vassal +19 more
TL;DR: A nationwide safe access to crz for patients with an ALK, MET or ROS1 positive (+) tumor, the French National Cancer Institute launched the AcSe program, funding both access to tumor molecular diagnosis and an exploratory multi-tumor 2-stage design phase II trial.